Fortress Biotech (FBIO) 10-Q1 Nov 132013 Q3 Quarterly reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
Document and Entity Information	Sep. 30, 2013	Oct. 30, 2013
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-13	'
Document Fiscal Year Focus	'2013	'
Document Fiscal Period Focus	'Q3	'
Entity Registrant Name	'CORONADO BIOSCIENCES INC	'
Entity Central Index Key	'0001429260	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	35,611,883

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Sep. 30, 2013	Dec. 31, 2012
Current Assets:	'	'
Cash and cash equivalents	$106,267	$40,199
Prepaid and other current assets	279	393
Total current assets	106,546	40,592
Property and equipment, net	452	51
Other assets	109	349
Total Assets	107,107	40,992
Current Liabilities:	'	'
Accounts payable	1,114	1,029
Interest payable	116	119
Accrued expenses	2,352	2,185
Current portion of note payable	6,062	1,799
Total current liabilities	9,644	5,132
Note payable	8,408	12,386
Other long-term liabilities	1,541	1,441
Total Liabilities	19,593	18,959
Commitments and Contingencies	'	'
Stockholders' Equity:	'	'
Common Stock, $.001 par value, 100,000,000 and 50,000,000 shares authorized as of September 30, 2013 and December 31, 2012, respectively, 35,255,680 and 24,400,754 shares issued and outstanding as of September 30, 2013 and December 31, 2012, respectively	35	24
Additional paid-in capital	199,023	106,193
Deficit accumulated during development stage	-111,544	-84,184
Total Stockholders' Equity	87,514	22,033
Total Liabilities and Stockholders' Equity	107,107	40,992
Series C Convertible Preferred Stock [Member]	'	'
Stockholders' Equity:	'	'
Convertible Preferred Stock, $.001 par value, 452,923 and 584,390 Series C shares authorized, 0 shares issued and outstanding as of September 30, 2013 and December 31, 2012, respectively	'	'

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Common Stock, par value	$0.00	$0.00
Common Stock, shares authorized	100,000,000	50,000,000
Common Stock, shares issued	35,255,680	24,400,754
Common Stock, shares outstanding	35,255,680	24,400,754
Series C Convertible Preferred Stock [Member]	'	'
Preferred Stock, par value	$0.00	$0.00
Preferred Stock, shares authorized	452,923	584,390
Preferred Stock, shares issued	0	0
Preferred Stock, shares outstanding	0	0

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	3 Months Ended		9 Months Ended		87 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Operating expenses:	'	'	'	'	'
Research and development	$5,361	$3,777	$19,130	$12,893	$61,139
General and administrative	2,143	2,054	7,126	5,984	23,405
In-process research and development	'	'	'	'	21,749
Loss from operations	-7,504	-5,831	-26,256	-18,877	-106,293
Interest income	165	79	350	152	830
Interest expense	-493	-183	-1,454	-220	-5,407
Other income	'	'	'	'	733
Warrant expense	'	'	'	'	-1,407
Net loss	-7,832	-5,935	-27,360	-18,945	-111,544
Common Stock dividend to Series A Convertible Preferred Stockholders	'	'	'	'	-5,861
Net loss attributed to Common Stock	($7,832)	($5,935)	($27,360)	($18,945)	($117,405)
Basic and diluted net loss per common share	($0.24)	($0.24)	($0.95)	($0.91)	'
Weighted average common shares outstanding - basic and diluted	32,634,683	24,375,749	28,664,822	20,738,007	'

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	9 Months Ended		87 Months Ended
Consolidated Statements of Cash Flows (USD $)	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Cash flows from operating activities:	'	'	'
Net loss	($27,360,000)	($18,945,000)	($111,544,000)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'	'
Stock-based compensation expense	4,072,000	2,173,000	11,584,000
Acquired in-process research and development	'	'	21,749,000
Noncash interest expense	400,000	35,000	2,298,000
Noncash interest expense-related parties	'	'	286,000
Contribution of services by stockholder	'	'	130,000
Issuance of Common Stock to non-employee for services	'	'	121,000
Change in fair value of Common Stock warrant liability	'	'	234,000
Change in fair value of embedded conversion feature	'	'	831,000
Change in fair value of Preferred Stock warrant liability	'	'	1,407,000
Depreciation expense	11,000	'	55,000
Changes in operating assets and liabilities:	'	'	'
Prepaid and other current assets	114,000	-324,000	-339,000
Interest payable	-3,000	97,000	116,000
Accounts payable and accrued expenses	252,000	875,000	3,466,000
Net cash used in operating activities	-22,514,000	-16,089,000	-69,606,000
Cash flows from investing activities:	'	'	'
Purchase of property and equipment	-187,000	'	-507,000
Purchase of in-process research and development	'	'	-3,843,000
Net cash used in investing activities	-187,000	'	-4,350,000
Cash flows from financing activities:	'	'	'
Proceeds from PCP notes payable-related party	'	'	570,000
Payment of PCP notes payable-related party	'	'	-570,000
Payment of PCP notes payable-Asphelia asset purchase	'	-750,000	-750,000
Proceeds from notes payable-related parties	'	'	2,221,000
Proceeds from borrowings under line of credit	'	'	80,000
Payment of line of credit	'	'	-80,000
Proceeds from Senior Convertible Notes	'	'	7,570,000
Payment of debt issue costs	'	'	-737,000
Payment of notes payable-related parties	'	'	-600,000
Proceeds from issuance of Common Stock	90,629,000	28,750,000	119,682,000
Payment of costs related to the issuance of Common Stock	-1,860,000	-2,305,000	-4,165,000
Net cash provided by financing activities	88,769,000	40,407,000	180,223,000
Increase in cash and cash equivalents	66,068,000	24,318,000	106,267,000
Cash and cash equivalents-beginning of period	40,199,000	23,160,000	'
Cash and cash equivalents-end of period	106,267,000	47,478,000	106,267,000
Supplemental disclosure of cash flow information:	'	'	'
Cash paid for interest	1,052,000	36,000	1,609,000
Supplemental disclosure of non-cash financing and investing activities:	'	'	'
Assumption of PCP Note related to Asphelia Asset Purchase	'	'	750,000
Issuance of Warrant related to Hercules Note	1,098	'	'
Hercules Note [Member]	'	'	'
Cash flows from financing activities:	'	'	'
Proceeds from issuance of Hercules Note	'	15,000,000	15,000,000
Payment of debt issue costs	'	-288,000	-288,000
Supplemental disclosure of non-cash financing and investing activities:	'	'	'
Issuance of Warrant related to Hercules Note	'	'	323,000
Series B Convertible Preferred Stock [Member]	'	'	'
Supplemental disclosure of non-cash financing and investing activities:	'	'	'
Issuance of Convertible Preferred Stock Series B for purchase of assets	'	'	16,114,000
Series C Convertible Preferred Stock [Member]	'	'	'
Cash flows from financing activities:	'	'	'
Proceeds from issuance of Convertible Preferred Stock	'	'	25,784,000
Payment of costs related to the issuance of Convertible Preferred Stock	'	'	-2,884,000
Supplemental disclosure of non-cash financing and investing activities:	'	'	'
Issuance of Convertible Preferred Stock Series C warrants	'	'	1,286,000
Series A Convertible Preferred Stock [Member]	'	'	'
Cash flows from financing activities:	'	'	'
Proceeds from issuance of Convertible Preferred Stock	'	'	21,681,000
Payment of costs related to the issuance of Convertible Preferred Stock	'	'	-2,291,000
Supplemental disclosure of non-cash financing and investing activities:	'	'	'
Issuance of Common Stock warrants related to the Convertible Preferred Stock Series A financing	'	'	621,000
Conversion of Senior Convertible Notes into Convertible Preferred Stock Series A	'	'	8,601,000
Conversion of notes payable-related parties into Convertible Preferred Stock Series A	'	'	1,907,000
Series A, B and C Convertible Preferred Stock [Member]	'	'	'
Supplemental disclosure of non-cash financing and investing activities:	'	'	'
Issuance of Common Stock for Convertible Preferred Stock Series A, B and C	'	'	$67,004,000

Organization_and_Description_o

Organization and Description of Business	9 Months Ended
Organization and Description of Business	Sep. 30, 2013
Accounting Policies [Abstract]	'
Organization and Description of Business	'
	1. Organization and Description of Business
	Coronado Biosciences, Inc. (the “Company”), incorporated in Delaware on June 28, 2006 (date of inception), is a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer.
	Development-Stage Risks and Liquidity
	The Company is a development-stage enterprise. Activities to date include development of key compounds, establishing pre-commercial relationships, hiring qualified personnel and raising capital to fund operations. The Company continues to report as a development stage enterprise since planned principal operations have not yet commenced. Since inception, no revenue has been recognized.
	On October 14, 2013 the Company reported that the TRUST-I study, its phase 2 randomized, double-blind, placebo-controlled, U.S. multi-centered study to evaluate the safety and efficacy of TSO in Crohn’s disease, did not meet its primary endpoint of improving response, defined as a 100-point decrease in the Crohn’s Disease Activity Index (CDAI), nor the key secondary endpoint of remission, defined as achieving CDAI < 150 points. In the overall patient population, response rate of patients on TSO did not separate from that of placebo.
	The Company’s development partner for TSO in Crohn’s disease, Dr. Falk Pharma GmbH, is conducting TRUST-II, a phase 2, double-blind, randomized, placebo-controlled, multi-center study in Europe to evaluate the efficacy and safety of three different dosages of TSO in active Crohn’s disease. The results from a second interim analysis are expected in the fourth quarter of 2013.
	The Company has incurred losses and experienced negative operating cash flows since inception and has an accumulated deficit of $111.5 million as of September 30, 2013. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant sales from its product candidates. To date, the Company’s operations have been funded primarily by issuing equity and debt securities. For the nine months ended September 30, 2013, the Company issued 10,352,219 shares of Common Stock for total net proceeds of $88.0 million under the Company’s 2012 and 2013 ATMs (See Note 9). Since September 30, 2013 through October 2, 2013, the Company sold an additional 206,203 shares of Common Stock for net proceeds of $1.4 million under its 2013 ATM. (See Note 9.) The Company expects to incur substantial expenditures in the foreseeable future for the research, development and potential commercialization of its product candidates. The Company is continuing to evaluate the data from the TRUST-I trial and other current data on TSO and is awaiting the results of the TRUST-II trial to determine the future development plan for TSO. Until it has completed that process and made a determination regarding the future development for TSO, it does not expect its current level of expenditures to increase in the next 12 months. However, the Company believes that cash and cash equivalents on hand are sufficient to sustain operations at least for the next 12 months. The Company would require additional financing to fully develop and obtain regulatory approvals for its product candidates, fund operating losses, establish manufacturing, and, if deemed appropriate, sales and marketing capabilities. The Company expects that it would need to seek funds through public or private equity or debt financings, collaborative or other arrangements with corporate sources, or through other sources of financing. Adequate additional funding may not be available to the Company on acceptable terms or at all. The Company’s failure to raise capital as and when needed would have a negative impact on its financial condition and its ability to pursue its business strategies. If adequate funds are not available to the Company, the Company will be required to delay, reduce or eliminate research and development programs, and pursue merger or acquisition strategies, if possible.
	Operations of the Company are subject to other risks and uncertainties, including, but not limited to, uncertainty of product candidate development; technological uncertainty; dependence on collaborative partners; uncertainty regarding patents and proprietary rights; regulatory approvals and other comprehensive government regulations; having no commercial manufacturing, marketing or sales capability or experience; and dependence on key personnel. Any significant delays in the development of product candidates, failures of product candidates to successfully meet clinical-trial goals or delays in marketing of products could have a material adverse effect on the Company’s business and financial results.
	The Company sources certain critical components from single source suppliers. If the Company is required to purchase these components from an alternative source, it could adversely affect development of the Company’s product candidates.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	9 Months Ended
Summary of Significant Accounting Policies	Sep. 30, 2013
Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	2. Summary of Significant Accounting Policies

	Basis of Presentation and Principles of Consolidation

	The accompanying unaudited interim consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In management’s opinion, the unaudited interim consolidated financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of our balances and results for the periods presented. Certain information and footnote disclosures normally included in the Company’s annual financial statements prepared in accordance with GAAP have been condensed or omitted. These consolidated financial statement results are not necessarily indicative of results to be expected for the full fiscal year or any future period. The consolidated balance sheet at December 31, 2012 has been derived from the audited consolidated financial statements at that date. The consolidated financial statements and related disclosures have been prepared with the presumption that users of the consolidated financial statements have read or have access to the audited consolidated financial statements for the preceding fiscal year. Accordingly, these consolidated financial statements should be read in conjunction with the Company’s Form 10-K which was initially filed with the United States Securities and Exchange Commission, or SEC, on March 18, 2013.

	The Company’s unaudited consolidated financial statements include the accounts of the Company and its 100% owned subsidiary, Innmune Limited. All intercompany balances and transactions have been eliminated.

	The preparation of the Company’s unaudited consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited consolidated financial statements and the reported amounts of expenses during the reporting period.

	Use of Estimates

	The Company’s consolidated financial statements include certain amounts that are based on management’s best estimates and judgments. The Company’s significant estimates include, but are not limited to, useful lives assigned to long-lived assets, compensation expenses related to Common Stock, warrants and options, accrued expenses, provisions for income taxes and contingencies. Due to the uncertainty inherent in such estimates, actual results may differ from our estimates.

	Concentration of Risk

	The Company is currently completely dependent on third party manufacturers for product supply. In particular, the Company relies exclusively on Ovamed GmbH (“Ovamed”) to supply it with its requirements of Trichuris suisova (“TSO”). Ovamed is the sole supplier of this product, which it is currently producing at only one facility in Germany, where it is also producing product for others, including Dr. Falk Pharma GmbH (“Falk”). Ovamed also relies on certain other suppliers for materials and services. Also, the Company currently relies on BioReliance Corporation, Progenitor Cell Therapy LLC and other third parties for its CNDO–109 product requirements. The Company’s clinical development programs would be adversely affected by a significant interruption in obtaining clinical trial supplies.

	Deferred Financing Costs

	Financing costs incurred in connection with the Hercules Technology Growth Capital, Inc. (“Hercules”) note payable were deferred and are being amortized over the appropriate expected life based on the term of the note using the effective interest rate method. As of September 30, 2013 the Company has deferred financing costs of $48,000 recorded in other assets in the accompanying balance sheet. (See Note 4)

	Stock-Based Compensation

	The Company expenses stock-based compensation to employees over the requisite service period based on the estimated grant-date fair value of the awards and forfeiture rates. For stock-based compensation awards to non-employees, the Company remeasures the fair value of the non-employee awards at each reporting period prior to vesting and finally at the vesting date of the award. Changes in the estimated fair value of these non-employee awards are recognized as compensation expense in the period of change.

	The assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment.

	Income Taxes

	The Company records income taxes using the asset and liability method. Deferred income tax assets and liabilities are recognized for the future tax effects attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective income tax bases, and operating loss and tax credit carryforwards. The Company establishes a valuation allowance if it is more likely than not that the deferred tax assets will not be recovered based on an evaluation of objective verifiable evidence. For tax positions that are more likely than not of being sustained upon audit, the Company recognizes the largest amount of the benefit that is greater than 50% likely of being realized. For tax positions that are not more likely than not of being sustained upon audit, the Company does not recognize any portion of the benefit.

	Comprehensive Loss

	The Company’s comprehensive loss is equal to its net loss for all periods presented.

Net_Loss_Per_Common_Share

Net Loss Per Common Share	9 Months Ended
Net Loss Per Common Share	Sep. 30, 2013
Earnings Per Share [Abstract]	'
Net Loss Per Common Share	'
	3. Net Loss Per Common Share

	The Company calculates loss per share using the two-class method, which is an earnings allocation formula that determines earnings per share for Common Stock and participating securities according to dividends declared and non-forfeitable participation rights in undistributed earnings. Under this method, all earnings (distributed and undistributed) are allocated to Common Stock and participating securities based on their respective rights to receive dividends. Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of Common Stock outstanding during the period, without consideration for Common Stock equivalents. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of Common Stock and Common Stock equivalents outstanding for the period.

	A calculation of basic and diluted net loss per share follows:




	($ in thousands except share and per share amounts)	For the three months ended						For the nine months ended
		September 30,						September 30,
		2013			2012			2013			2012
	Historical net loss per share:
	Numerator:
	Net loss attributed to common stockholders	$	(7,832	)	$	(5,935	)	$	(27,360	)	$	(18,945	)
	Denominator:
	Weighted-average common shares outstanding—denominator for basic and diluted net loss per share		32,634,683			24,375,749			28,664,822			20,738,007

	Basic and diluted net loss per common share attributed to common stockholders	$	(0.24	)	$	(0.24	)	$	(0.95	)	$	(0.91	)

	The Company’s potential dilutive securities which include stock options and warrants have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average Common Stock outstanding used to calculate both basic and diluted net loss per share are the same.

	The following shares of potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding, as the effect of including such securities would be antidilutive:




		For the three months ended						For the nine months ended
		September 30,						September 30,
		2013			2012			2013			2012
	Warrants to purchase Common Stock		1,040,921			1,090,294			1,097,869			1,067,187
	Options to purchase Common Stock		4,285,503			2,369,342			4,130,936			2,231,425

			5,326,424			3,459,636			5,228,805			3,298,612

Debt_and_Interest

Debt and Interest	9 Months Ended
Debt and Interest	Sep. 30, 2013
Debt Disclosure [Abstract]	'
Debt and Interest	'
	4. Debt and Interest
	Interest expense of $493,000 and $1,453,000 for the three and nine months ended September 30, 2013, respectively, principally related to the $15 million term loan with Hercules Technology Growth Capital (“Hercules Note”), and include $355,000 and $1,052,000 in cash interest for the three and nine months ended September 30, 2013, respectively, and $99,000 and $286,000 related to accretion of the debt discount for the three and nine months ended September 30, 2013, respectively. At September 30, 2013, the current portion of the Hercules Note was $6.1 million and noncurrent portion was $8.9 million, net of the debt discount of $530,000. The Company made its first principal payment of $446,000 on October 1, 2013.
	In 2012, we acquired from Ovamed manufacturing rights for TSO in North and South America and Japan, the Coronado Territory, and agreed to pay Ovamed $1.5 million in three equal installments of $500,000 commencing in December 2014 and ending in December 2016. The Company recorded this obligation at December 31, 2012 as an other long-term liability at its estimated net present value of $1.0 million, using an effective interest rate of 12.33%, and is accreting the carrying amount up to the $1.5 million obligation. Accretion of the obligation was $34,500 and $100,500 for the three and nine months ended September 30, 2013, respectively and recorded as interest expense.

Property_and_Equipment

Property and Equipment	9 Months Ended
Property and Equipment	Sep. 30, 2013
Property Plant And Equipment [Abstract]	'
Property and Equipment	'
	5. Property and Equipment
	Property and equipment consisted of the following:


	($ in thousands)	Useful Life		As of September 30,			As of December 31,
	($ in thousands)	(Years)		2013			2012
	Construction in progress		N/A	$	372		$	—
	Computer equipment		3		12			10
	Furniture and fixtures		5		70			38
	Leasehold improvements		5		12			6

	Total property and equipment				466			54
	Less: Accumulated depreciation				(14	)		(3	)

	Property and equipment, net			$	452		$	51

	Construction in progress relates to payments made in connection with the build-out of our Woburn, Massachusetts manufacturing facility.

Accrued_Expenses_and_Other_Lon

Accrued Expenses and Other Long-Term Liabilities	9 Months Ended
Accrued Expenses and Other Long-Term Liabilities	Sep. 30, 2013
Text Block [Abstract]	'
Accrued Expenses and Other Long-Term Liabilities	'
	6. Accrued Expenses and Other Long-Term Liabilities
	Accrued expenses and other long-term liabilities consisted of the following:


		As of September 30,		As of December 31,
		2013		2012
	Accrued expenses:
	Salaries, bonuses and related benefits	$	582	$	1,064
	Severance		352		354
	Professional fees		399		320
	Research and development expenses		851		403
	State franchise taxes		56		—
	Other		112		44

	Total accrued expenses	$	2,352	$	2,185

	Other long-term liabilities:
	Hercules Note, end of term obligation	$	398	$	398
	Ovamed manufacturing rights		1,143		1,043

	Total other long-term liabilities	$	1,541	$	1,441

TSO

TSO	9 Months Ended
TSO	Sep. 30, 2013
Organization Consolidation And Presentation Of Financial Statements [Abstract]	'
TSO	'
	7. TSO
	Research Agreement
	On February 22, 2013, the Company and Freie Universität Berlin (“FU Berlin”) entered into a Research Agreement (the “Research Agreement”) to, among other things, identify and evaluate secretory proteins from TSO (the “Project”). The duration of the Project is expected to be four years, during which the Company will pay FU Berlin a total maximum amount of approximately €648,000, or approximately $853,000 in research fees and FU Berlin will periodically produce written progress reports on the Project. The Research Agreement terminates on the later of the date that the last payment or report is due, subject to early termination by either party upon three months written notice for cause or without cause. If the Company terminates the Research Agreement, the Company must pay FU Berlin a termination fee comprised primarily of unpaid research fees due on the first payment date after which termination occurred (subject to adjustment), except where termination is due to a breach by FU Berlin which it fails to cure within 60 days’ notice or due to FU Berlin’s bankruptcy. For the three and nine months ended September 30, 2013, the Company incurred sponsored research expense of $52,500 and $127,400, respectively, which was reflected in research and development expense.
	On February 22, 2013, the Company and FU Berlin also entered into a Joint Ownership and Exclusive License Agreement (the “JOELA”), pursuant to which the Company agreed to jointly own all intellectual property arising from the Project (the “Joint Intellectual Property”). FU Berlin also granted the Company (a) an exclusive worldwide license (including the right to sublicense) to its interest in the Joint Intellectual Property and its know-how related to the Project (the “Licensed IP”), and (b) the right to commercialize products that, without the licenses granted under the JOELA, would infringe the Licensed IP (the “Licensed Products”). FU Berlin retains the non-exclusive and non-transferable right to use the Licensed IP for its own internal, academic purposes. Pursuant to the JOELA, the Company will pay FU Berlin a total maximum amount of €3,830,000, or approximately $4,982,000 in potential milestone payments, based primarily on the achievement of clinical development and regulatory milestones, and royalties on potential net sales of products ranging from 1.0% to 2.5%. The JOELA continues until the last-to-expire patent in any country, subject to early termination by either party without penalty if the other party breaches the JOELA and the breach is not cured within 60 days after receiving notice of the breach or if a party is in bankruptcy. The Company also has the right to terminate the JOELA after giving FU Berlin 60 days written notice of a regulatory action that affects the safety, efficacy or marketability of the Licensed Products or if the Company cannot obtain sufficient materials to conduct trials, or upon 180 days written notice for any reason.
	In connection with the Research Agreement and JOELA, the Company entered into a License and Sublicense Agreement (the “LSA”) with Ovamed GmbH (“Ovamed”) on February 22, 2013, pursuant to which the Company licensed is rights to the Joint Intellectual Property and sublicensed its rights to the Licensed IP to Ovamed in all countries outside North America, South America and Japan (the “Ovamed Territory”). Pursuant to the LSA, Ovamed would pay the Company a total maximum amount of €1,025,000, or approximately $1,333,000, based primarily on the achievement of regulatory milestones, and royalties on potential net sales of products ranging from 1.0% to 2.5%, subject to adjustment, in each case equal to the comparable payments due under the JOELA. The LSA continues until the last-to-expire patent in any country in the Ovamed Territory, subject to early termination by either party upon the same terms as in the JOELA.
	On February 22, 2013, Coronado, Ovamed and FU Berlin entered into a Letter Agreement (the “Letter Agreement”) to amend a Material Transfer Agreement dated May 14, 2012 by and between Ovamed and FU Berlin. The Letter Agreement provides that Ovamed will retain a 10% interest in FU Berlin’s rights to the Joint Intellectual Property in the Ovamed Territory. It also grants Ovamed certain rights if FU Berlin terminates the JOELA due to the Company’s breach, including the right to have the JOELA survive and the Company’s rights and obligations thereunder assigned to Ovamed.

Fair_Value_Measurement

Fair Value Measurement	9 Months Ended
Fair Value Measurement	Sep. 30, 2013
Fair Value Disclosures [Abstract]	'
Fair Value Measurement	'
	8. Fair Value Measurement

	The Company follows accounting guidance on fair value measurements for financial assets and liabilities measured on a recurring basis. Under the accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability.

	The accounting guidance requires fair value measurements be classified and disclosed in one of the following three categories:

	Level 1: Quoted prices in active markets for identical assets or liabilities.

	Level 2: Observable inputs other than Level 1 prices, for similar assets or liabilities that are directly or indirectly observable in the marketplace.

	Level 3: Unobservable inputs which are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.

	The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.

	Certain of the Company’s financial instruments are not measured at fair value on a recurring basis but are recorded at amounts that approximate their fair value due to their liquid or short-term nature, such as cash and cash equivalents, accounts payable, accrued expenses and other current liabilities. The carrying value of the accrued Ovamed manufacturing rights license included in long-term liabilities has been recorded at its net present value, which approximates its fair value.

	The estimated fair value of the Hercules Note at September 30, 2013 computed using the effective interest rate method is $14.9 million. The effective interest rate considers the fair value of the warrant issued in connection with the loan, loan issuance costs and the deferred charge. The fair value measurement utilizes inputs that are categorized as Level 3.

Common_Stock

Common Stock	9 Months Ended
Common Stock	Sep. 30, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Common Stock	'
	9. Common Stock
	At Market Issuance Programs
	In September 2012, the Company filed a shelf registration statement on Form S-3 (the “2012 Form S-3”) pursuant to which it could sell up to a total of $75.0 million of its equity securities and, in October 2012, entered into an At Market Issuance Sales Agreement with MLV & Co LLC (“MLV”) to issue and sell up to $30.0 million of shares of Common Stock under the 2012 Form S-3 (the “2012 ATM”). Upon completion of the 2012 ATM, in April 2013, the Company entered into a new At Market Issuance Sales Agreement with MLV whereby it could issue and sell up to $45.0 million of shares of Common Stock under the 2012 Form S-3 (the “2013 ATM”).

	In July 2013, the Company filed a shelf registration statement on Form S-3 (the “2013 Form S-3”), which was declared effective on August 19, 2013.The Company may sell up to a total of $200.0 million of its equity securities under the 2013 Form S-3. In connection with the 2013 Form S-3, the Company amended its 2013 ATM with MLV such that it may offer and sell additional shares of Common Stock having an aggregate offering price of up to $70.0 million from time to time under the 2013 Form S-3 (the “Amended 2013 ATM”). Pursuant to the terms of the ATM’s with MLV, the Company will pay directly to MLV fees of up to 3% of the gross proceeds of the ATM then in effect. In the nine months ended September 30, 2013, the Company sold 10,352,219 shares of Common Stock under the ATMs and received net proceeds of $88.0 million. Since September 30, 2013 and through October 2, 2013, the Company sold an additional 206,203 shares of Common Stock for net proceeds of $1.4 million under the Amended 2013 ATM.
	Authorized Shares
	On September 30, 2013, the Company held a Special Meeting of Stockholders. At the meeting the Company’s Stockholders’ approved an amended and restated certificate of incorporation, to increase the number of authorized shares of capital stock from 65,000,000 shares to 115,000,000 shares and to increase the number of authorized shares of Common Stock from 50,000,000 to 100,000,000.
	Stockholders’ Equity
	The following table summarizes stockholders’ equity activity for the nine months ended September 30, 2013 ($000’s):


		Common Shares							Additional		Deficit			Total
									Paid-in		accumulated			Stockholders’
											during
											development
		Shares				Amount			Capital		stage			equity
	Balance at December 31, 2012		24,400,754			$	24		$	106,193	$	(84,184	)	$	22,033
	Exercise of Common Stock options		400,157				1			679		—			680
	Exercise of Common Stock warrants		81,045				—			—		—			—
	Sale of Common Stock under ATM programs		10,352,219				10			87,996		—			88,006
	Issuance of Common Stock related to the ESPP		21,505				—			83		—			83
	Stock-based compensation expense		—				—			4,072		—			4,072
	Net loss		—				—			—		(27,360	)		(27,360	)

	Balance at September 30, 2013		35,255,680			$	35		$	199,023	$	(111,544	)	$	87,514

	Stock-based Compensation Plans
	The Company has three equity compensation plans, the Coronado Biosciences, Inc. 2007 Stock Incentive Plan, the Coronado Biosciences, Inc. 2013 Stock Incentive Plan, (the “2013 Plan”) and the 2012 Employee Stock Purchase Plan (the “ESPP”). At the Company’s Annual Meeting of Stockholders held on June 19, 2013, the stockholders approved the 2013 Plan, authorizing the Company to grant up to 2,300,000 shares of Common Stock to eligible employees, directors and consultants in the form of stock options, stock appreciation rights, restricted stock awards, and restricted stock unit awards. The Board of Directors determines the amount, terms and exercisability provisions of grants under the 2013 Plan.
	Compensation Expense. The following table summarizes the stock-based compensation expense from awards, including stock options and restricted Common Stock awards to employees and non-employees, compensation expense for the ESPP and warrants to non-employees for the nine months ended September 30, 2013 and 2012, and from the period June 28, 2006 (date of inception) to date.


		For the nine months ended							Period from
		September 30,							June 28, 2006
									(date of
									inception) to
									September 30,
	($ in thousands)	2013				2012			2013
	Employee awards	$	3,174			$	1,336		$	6,380
	Non-employee awards		758				412			4,171
	Non-employee warrants		140				425			1,033

	Total stock-based compensation expense	$	4,072			$	2,173		$	11,584

	The following table summarizes stock option activity since December 31, 2012:


		Outstanding Options									Weighted
											Average
											Remaining
											Contractual
											Life (in
	($ in thousands except per share amounts)	Number of				Weighted			Total		years)
		Shares				Average			Weighted
						Exercise			Average
						Price			Intrinsic
									Value
	At December 31, 2012		2,519,070			$	3.37		$	2,860		8.5
	Options granted		2,031,590				6.07
	Options exercised		(400,157	)			1.7
	Options cancelled		(20,000	)			1.93

	At September 30, 2013		4,130,503			$	4.87		$	8,830		8.6

Options vested and expected to vest		4,130,503			$	4.87		$	8,830		8.6
Options vested and exercisable		1,080,899			$	3.95		$	4,269		7.7
Total weighted average intrinsic value for all computations as of September 30, 2013 is based on the closing price of the Company’s common stock on September 30, 2013 of $7.01 per share.
As of September 30, 2013 the Company had unrecognized stock-based compensation expense related to unvested stock options to employees and non-employees of $9.1 million, which is expected to be recognized over the remaining weighted-average vesting period of 1.5 years.
On May 31, 2013, the Company issued 21,505 shares of Common Stock under Company’s Employee Stock Purchase Plan (“ESPP”). Common Stock was issued at $3.88 per share, which represents 85% of the closing price of $4.56 of the Common Stock on December 3, 2012.
Warrants to Purchase Common Stock
For the nine months ended September 30, 2013, the Company issued 80,705 shares of Common Stock pursuant to the cashless exercise of 158,429 warrants at a weighted average exercise price of $5.02, and 340 shares of Common Stock for cash proceeds of $1,098.

Market_Capitalization_Bonuses_

Market Capitalization Bonuses and Executive Officer Resignations and Agreements	9 Months Ended
	Sep. 30, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Market Capitalization Bonuses and Executive Officer Resignations and Agreements	'
	10. Market Capitalization Bonuses and Executive Officer Resignations and Agreements
	Market Capitalization Bonuses
	Pursuant to the employment agreements with certain executive officers, the Company is obligated to pay certain bonuses to these executive officers upon attainment of specified market capitalizations and trading volumes. The first market capitalization bonus of $231,250 was earned and paid in the three months ended March 31, 2013 upon attainment of a $125 million market capitalization and a 30-day trading share volume in excess of 50,000 shares per day. The second market capitalization bonus of $312,500 was earned and paid in the three months ended June 30, 2013 upon attainment of a $250 million market capitalization and a 30-day trading share volume in excess of 100,000 shares per day. Expense related to these bonuses were reflected in the periods in which they were earned.
	Executive Officer Resignations
	On April 22, 2013, Dr. Bobby W. Sandage, Jr. resigned as president and director of the Company. In accordance with Dr. Sandage’s employment agreement, as amended, Dr. Sandage is entitled to receive his salary and COBRA benefits for twelve months from the date of his resignation. The Company recorded a severance liability of $445,000 for these obligations in the three-month period ended June 30, 2013. For the three months ended September 30, 2013, the Company paid $107,000 of the severance obligation to Dr. Sandage and $94,900 to Dr. Glenn Cooper in connection with his severance arrangement recorded in 2012. For the nine months ended September 30, 2013 a total of $446,200 was paid to Drs. Sandage and Cooper.

Lease

Lease	9 Months Ended
Lease	Sep. 30, 2013
Leases [Abstract]	'
Lease	'
	11. Lease
	New York City Office Lease
	In April 2013, the Company entered into a three-year lease for approximately 1,500 square feet of office space in New York City, New York at an average annual rent of approximately $122,000. Total rent expense for the term of this lease will be approximately $366,000. The Company commenced occupancy of this space in May 2013.

Subsequent_Events

Subsequent Events	9 Months Ended
Subsequent Events	Sep. 30, 2013
Subsequent Events [Abstract]	'
Subsequent Events	'
	12. Subsequent Events
	TRUST-I Data
	On October 14, 2013, the Company reported that the TRUST-I study, its phase 2 randomized, double-blind, placebo-controlled, U.S. multi-centered study to evaluate the safety and efficacy of TSO in Crohn’s disease, did not meet its primary endpoint of improving response, defined as a 100-point decrease in the Crohn’s Disease Activity Index (CDAI), nor the key secondary endpoint of remission, defined as achieving CDAI < 150 points. In the overall patient population, response rate of patients on TSO did not separate from that of placebo.
	The Company’s development partner for TSO in Crohn’s disease, Dr. Falk Pharma GmbH, is conducting TRUST-II, a phase 2, double-blind, randomized, placebo-controlled, multi-center study in Europe to evaluate the efficacy and safety of three different dosages of TSO in active Crohn’s disease. The results from a second interim analysis are expected in the fourth quarter of 2013.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	9 Months Ended
Summary of Significant Accounting Policies (Policies)	Sep. 30, 2013
Accounting Policies [Abstract]	'
Basis of Presentation and Principles of Consolidation	'
	Basis of Presentation and Principles of Consolidation
	The accompanying unaudited interim consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In management’s opinion, the unaudited interim consolidated financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of our balances and results for the periods presented. Certain information and footnote disclosures normally included in the Company’s annual financial statements prepared in accordance with GAAP have been condensed or omitted. These consolidated financial statement results are not necessarily indicative of results to be expected for the full fiscal year or any future period.

	The consolidated balance sheet at December 31, 2012 has been derived from the audited consolidated financial statements at that date. The consolidated financial statements and related disclosures have been prepared with the presumption that users of the consolidated financial statements have read or have access to the audited consolidated financial statements for the preceding fiscal year. Accordingly, these consolidated financial statements should be read in conjunction with the Company’s Form 10-K which was initially filed with the United States Securities and Exchange Commission, or SEC, on March 18, 2013.
	The Company’s unaudited consolidated financial statements include the accounts of the Company and its 100% owned subsidiary, Innmune Limited. All intercompany balances and transactions have been eliminated.
	The preparation of the Company’s unaudited consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited consolidated financial statements and the reported amounts of expenses during the reporting period.
Use of Estimates	'
	Use of Estimates
	The Company’s consolidated financial statements include certain amounts that are based on management’s best estimates and judgments. The Company’s significant estimates include, but are not limited to, useful lives assigned to long-lived assets, compensation expenses related to Common Stock, warrants and options, accrued expenses, provisions for income taxes and contingencies. Due to the uncertainty inherent in such estimates, actual results may differ from our estimates.
Concentration of Risk	'
	Concentration of Risk
	The Company is currently completely dependent on third party manufacturers for product supply. In particular, the Company relies exclusively on Ovamed GmbH (“Ovamed”) to supply it with its requirements of Trichuris suis ova (“TSO”). Ovamed is the sole supplier of this product, which it is currently producing at only one facility in Germany, where it is also producing product for others, including Dr. Falk Pharma GmbH (“Falk”). Ovamed also relies on certain other suppliers for materials and services. Also, the Company currently relies on BioReliance Corporation, Progenitor Cell Therapy LLC and other third parties for its CNDO–109 product requirements. The Company’s clinical development programs would be adversely affected by a significant interruption in obtaining clinical trial supplies.
Deferred Financing Costs	'
	Deferred Financing Costs
	Financing costs incurred in connection with the Hercules Technology Growth Capital, Inc. (“Hercules”) note payable were deferred and are being amortized over the appropriate expected life based on the term of the note using the effective interest rate method. As of September 30, 2013 the Company has deferred financing costs of $48,000 recorded in other assets in the accompanying balance sheet. (See Note 4)
Stock-Based Compensation	'
	Stock-Based Compensation
	The Company expenses stock-based compensation to employees over the requisite service period based on the estimated grant-date fair value of the awards and forfeiture rates. For stock-based compensation awards to non-employees, the Company remeasures the fair value of the non-employee awards at each reporting period prior to vesting and finally at the vesting date of the award. Changes in the estimated fair value of these non-employee awards are recognized as compensation expense in the period of change.
	The assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment.
Income Taxes	'
	Income Taxes
	The Company records income taxes using the asset and liability method. Deferred income tax assets and liabilities are recognized for the future tax effects attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective income tax bases, and operating loss and tax credit carryforwards. The Company establishes a valuation allowance if it is more likely than not that the deferred tax assets will not be recovered based on an evaluation of objective verifiable evidence. For tax positions that are more likely than not of being sustained upon audit, the Company recognizes the largest amount of the benefit that is greater than 50% likely of being realized. For tax positions that are not more likely than not of being sustained upon audit, the Company does not recognize any portion of the benefit.
Comprehensive Loss	'
	Comprehensive Loss
	The Company’s comprehensive loss is equal to its net loss for all periods presented.

Net_Loss_Per_Common_Share_Tabl

Net Loss Per Common Share (Tables)	9 Months Ended
Net Loss Per Common Share (Tables)	Sep. 30, 2013
Earnings Per Share [Abstract]	'
Calculation of Basic and Diluted Net Loss Per Share	'
	A calculation of basic and diluted net loss per share follows:




	($ in thousands except share and per share amounts)	For the three months ended						For the nine months ended
		September 30,						September 30,
		2013			2012			2013			2012
	Historical net loss per share:
	Numerator:
	Net loss attributed to common stockholders	$	(7,832	)	$	(5,935	)	$	(27,360	)	$	(18,945	)
	Denominator:
	Weighted-average common shares outstanding—denominator for basic and diluted net loss per share		32,634,683			24,375,749			28,664,822			20,738,007

	Basic and diluted net loss per common share attributed to common stockholders	$	(0.24	)	$	(0.24	)	$	(0.95	)	$	(0.91	)

Computations of Diluted Weighted Average Shares Outstanding	'
	The following shares of potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding, as the effect of including such securities would be antidilutive:




		For the three months ended						For the nine months ended
		September 30,						September 30,
		2013			2012			2013			2012
	Warrants to purchase Common Stock		1,040,921			1,090,294			1,097,869			1,067,187
	Options to purchase Common Stock		4,285,503			2,369,342			4,130,936			2,231,425

			5,326,424			3,459,636			5,228,805			3,298,612

Property_and_Equipment_Tables

Property and Equipment (Tables)	9 Months Ended
Property and Equipment (Tables)	Sep. 30, 2013
Property Plant And Equipment [Abstract]	'
Components of Property and Equipment	'
	Property and equipment consisted of the following:


	($ in thousands)	Useful Life		As of September 30,			As of December 31,
	($ in thousands)	(Years)		2013			2012
	Construction in progress		N/A	$	372		$	—
	Computer equipment		3		12			10
	Furniture and fixtures		5		70			38
	Leasehold improvements		5		12			6

	Total property and equipment				466			54
	Less: Accumulated depreciation				(14	)		(3	)

	Property and equipment, net			$	452		$	51

Accrued_Expenses_and_Other_Lon1

Accrued Expenses and Other Long-Term Liabilities (Tables)	9 Months Ended
Accrued Expenses and Other Long-Term Liabilities (Tables)	Sep. 30, 2013
Text Block [Abstract]	'
Components of Accrued Expenses and Other Long-Term Liabilities	'
	Accrued expenses and other long-term liabilities consisted of the following:


		As of September 30,		As of December 31,
		2013		2012
	Accrued expenses:
	Salaries, bonuses and related benefits	$	582	$	1,064
	Severance		352		354
	Professional fees		399		320
	Research and development expenses		851		403
	State franchise taxes		56		—
	Other		112		44

	Total accrued expenses	$	2,352	$	2,185

	Other long-term liabilities:
	Hercules Note, end of term obligation	$	398	$	398
	Ovamed manufacturing rights		1,143		1,043

	Total other long-term liabilities	$	1,541	$	1,441

Common_Stock_Tables

Common Stock (Tables)	9 Months Ended
Common Stock (Tables)	Sep. 30, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Summary of Stockholders Equity Activity	'
	The following table summarizes stockholders’ equity activity for the nine months ended September 30, 2013 ($000’s):


		Common Shares					Additional		Deficit			Total
							Paid-in		accumulated			Stockholders’
									during
									development
		Shares			Amount		Capital		stage			equity
	Balance at December 31, 2012		24,400,754		$	24	$	106,193	$	(84,184	)	$	22,033
	Exercise of Common Stock options		400,157			1		679		—			680
	Exercise of Common Stock warrants		81,045			—		—		—			—
	Sale of Common Stock under ATM programs		10,352,219			10		87,996		—			88,006
	Issuance of Common Stock related to the ESPP		21,505			—		83		—			83
	Stock-based compensation expense		—			—		4,072		—			4,072
	Net loss		—			—		—		(27,360	)		(27,360	)

	Balance at September 30, 2013		35,255,680		$	35	$	199,023	$	(111,544	)	$	87,514

Components of Stock-Based Compensation Expenses	'
	Compensation Expense. The following table summarizes the stock-based compensation expense from awards, including stock options and restricted Common Stock awards to employees and non-employees, compensation expense for the ESPP and warrants to non-employees for the nine months ended September 30, 2013 and 2012, and from the period June 28, 2006 (date of inception) to date.


		For the nine months ended					Period from
		September 30,					June 28, 2006
							(date of
							inception) to
							September 30,
	($ in thousands)	2013			2012		2013
	Employee awards	$	3,174		$	1,336	$	6,380
	Non-employee awards		758			412		4,171
	Non-employee warrants		140			425		1,033

	Total stock-based compensation expense	$	4,072		$	2,173	$	11,584

Summary of Stock Option Activity	'
	The following table summarizes stock option activity since December 31, 2012:


		Outstanding Options							Weighted
									Average
									Remaining
									Contractual
									Life (in
	($ in thousands except per share amounts)	Number of			Weighted		Total		years)
		Shares			Average		Weighted
					Exercise		Average
					Price		Intrinsic
							Value
	At December 31, 2012		2,519,070		$	3.37	$	2,860		8.5
	Options granted		2,031,590			6.07
	Options exercised		(400,157	)		1.7
	Options cancelled		(20,000	)		1.93

	At September 30, 2013		4,130,503		$	4.87	$	8,830		8.6

	Options vested and expected to vest		4,130,503		$	4.87	$	8,830		8.6
	Options vested and exercisable		1,080,899		$	3.95	$	4,269		7.7

Organization_and_Description_o1

Organization and Description of Business - Additional Information (Detail) (USD $)	9 Months Ended		87 Months Ended		9 Months Ended	0 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2013	Oct. 02, 2013
					2012 and 2013 ATMs [Member]	Subsequent Event [Member]
						2013 ATM [Member]
Organization And Nature Of Business [Line Items]	'	'	'	'	'	'
Accumulated deficit	($111,544)	'	($111,544)	($84,184)	'	'
Public offering of common stock, shares	'	'	'	'	10,352,219	206,203
Net proceeds from public offering of common stock	$90,629	$28,750	$119,682	'	$88,000	$1,400

Summary_of_Significant_Account2

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Line Items]	'
Deferred financing costs	48,000
Minimum [Member]	'
Accounting Policies [Line Items]	'
Percentage of tax benefit likely of being realized	50.00%
Innmune Limited [Member]	'
Accounting Policies [Line Items]	'
Ownership percentage by parent	100.00%

Net_Loss_Per_Common_Share_Calc

Net Loss Per Common Share - Calculation of Basic and Diluted Net Loss Per Share (Detail) (USD $)	3 Months Ended		9 Months Ended		87 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Numerator:	'	'	'	'	'
Net loss attributed to common stockholders	($7,832)	($5,935)	($27,360)	($18,945)	($117,405)
Denominator:	'	'	'	'	'
Weighted-average common shares outstanding-denominator for basic and diluted net loss per share	32,634,683	24,375,749	28,664,822	20,738,007	'
Basic and diluted net loss per common share attributed to common stockholders	($0.24)	($0.24)	($0.95)	($0.91)	'

Net_Loss_Per_Common_Share_Comp

Net Loss Per Common Share - Computations of Diluted Weighted Average Shares Outstanding (Detail)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Total of weighted average shares outstanding	5,326,424	3,459,636	5,228,805	3,298,612
Warrants to Purchase Common Stock [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Total of weighted average shares outstanding	1,040,921	1,090,294	1,097,869	1,067,187
Options to Purchase Common Stock [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Total of weighted average shares outstanding	4,285,503	2,369,342	4,130,936	2,231,425

Debt_and_Interest_Additional_I

Debt and Interest - Additional Information (Detail) (USD $)

3 Months Ended

9 Months Ended

87 Months Ended

3 Months Ended

9 Months Ended

1 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Oct. 31, 2013

Sep. 30, 2013

Dec. 31, 2012

Hercules Note [Member]

Ovamed Manufacturing Rights [Member]

Subsequent Event [Member]

Installment

Debt Instrument [Line Items]

Accretion of obligation

$493,000

$183,000

$1,454,000

$220,000

$5,407,000

$493,000

$1,453,000

$34,500

$100,500

Term loan with Hercules Technology Growth Capital

15,000,000

Cash interest paid

355,000

1,052,000

Interest expenses accretion of debt discounts

99,000

286,000

Current portion of note payable

6,062,000

1,799,000

6,100,000

Non current portion of notes payable

8,408,000

12,386,000

8,900,000

Debt discount recorded

530,000

First principal payment made

446,000

Payment to acquire manufacturing rights

1,500,000

Number of manufacturing rights installments

Installment for manufacturing rights

500,000

Acquired intangible assets payment initiation date

'2014-12

Acquired intangible assets payment expiration date

'2016-12

Net present value of long term liabilities

1,000,000

Interest rate on net present value

12.33%

Carrying amount obligation

$1,500,000

Property_and_Equipment_Compone

Property and Equipment - Components of Property and Equipment (Detail) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Dec. 31, 2012
Property, Plant and Equipment [Line Items]	'	'
Total property and equipment	$466	$54
Less: Accumulated depreciation	-14	-3
Property and equipment, net	452	51
Construction in Progress [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Total property and equipment	372	'
Computer Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Total property and equipment	12	10
Useful Life (Years)	'3 years	'
Furniture and Fixtures [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Total property and equipment	70	38
Useful Life (Years)	'5 years	'
Leasehold Improvements [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Total property and equipment	$12	$6
Useful Life (Years)	'5 years	'

Accrued_Expenses_and_Other_Lon2

Accrued Expenses and Other Long-Term Liabilities - Components of Accrued Expenses and Other Long-Term Liabilities (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Sep. 30, 2013	Dec. 31, 2012
Accrued expenses:	'	'
Salaries, bonuses and related benefits	$582	$1,064
Severance	352	354
Professional fees	399	320
Research and development expenses	851	403
State franchise taxes	56	'
Other	112	44
Total accrued expenses	2,352	2,185
Other long-term liabilities:	'	'
Hercules Note, end of term obligation	398	398
Ovamed manufacturing rights	1,143	1,043
Total other long-term liabilities	$1,541	$1,441

TSO_Additional_Information_Det

TSO - Additional Information (Detail)

1 Months Ended

3 Months Ended

9 Months Ended

87 Months Ended

1 Months Ended

3 Months Ended

9 Months Ended

Feb. 22, 2013

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Feb. 22, 2013

Sep. 30, 2013

Feb. 22, 2013

USD ($)

Research and Development Arrangement [Member]

Joint Ownership and Exclusive License Agreement Fu Berlin [Member]

License and Sublicense Agreement with Ovamed GmbH [Member]

Maximum Potential Consideration Receivable upon Achievement of Milestone [Member]

USD ($)

EUR (€)

Minimum [Member]

Maximum [Member]

Research and Development Arrangement [Member]

Minimum [Member]

Maximum [Member]

USD ($)

EUR (€)

USD ($)

EUR (€)

Long-term Purchase Commitment [Line Items]

Expected project duration under research agreement

'4 years

Research fees to be paid under agreement

$853,000

€ 648,000

Written notice period under research agreement termination

'3 months

Research and development expense

5,361,000

3,777,000

19,130,000

12,893,000

61,139,000

52,500

127,400

Potential milestone payments based primarily on the achievement of clinical development and regulatory milestones

4,982,000

3,830,000

Percentage of royalty on net sales of products range

1.00%

2.50%

1.00%

2.50%

Notice period to cure termination due to breach

'60 days

Period of notice for termination of Joint Ownership and exclusive license agreement

'60 days

Period of Written notice for termination of Joint Ownership and exclusive license agreement

'180 days

Maximum potential payment based on achievement of regulatory milestones

$1,333,000

€ 1,025,000

Right Interest in Joint Intellectual Property

10.00%

Fair_Value_Measurement_Additio

Fair Value Measurement - Additional Information (Detail) (Fair Value, Measurements, Nonrecurring [Member], Hercules Note [Member], USD $)	Sep. 30, 2013
In Millions, unless otherwise specified	Sep. 30, 2013
Fair Value, Measurements, Nonrecurring [Member] \| Hercules Note [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Note payable	$14.90

Common_Stock_Additional_Inform

Common Stock - Additional Information (Detail) (USD $)

1 Months Ended

9 Months Ended

87 Months Ended

9 Months Ended

0 Months Ended

31-May-13

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Jul. 31, 2013

Dec. 31, 2012

Jun. 19, 2013

Jul. 31, 2013

Apr. 30, 2013

Sep. 30, 2013

Oct. 31, 2012

Sep. 30, 2013

Oct. 02, 2013

Plans

2013 Plan [Member]

2013 ATM [Member]

Market Issuance Sales Agreement [Member]

2012 ATM [Member]

2012 and 2013 ATMs [Member]

Subsequent Event [Member]

2013 ATM [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Common stock having an aggregate offering price

$75,000,000

$200,000,000

$45,000,000

$30,000,000

Public offering of common stock, shares

10,352,219

206,203

Net proceeds from public offering of common stock

90,629,000

28,750,000

119,682,000

88,000,000

1,400,000

Common stock having an aggregate offering price, additional amount

70,000,000

Maximum percentage of fee paid under agreement

3.00%

Number of authorized shares, capital stock

115,000,000

65,000,000

Number of authorized shares, common stock

100,000,000

50,000,000

Number of equity compensation plans

Common Stock to be issued as equity grants

2,300,000

Stock-based compensation expense related to all unvested stock option

9,100,000

Stock-based compensation weighted-average vesting period

'1 year 6 months

Closing price of common stock

$4.56

$7.01

Stock issued during period shares employee stock purchase plans

21,505

Shares issued under employee stock purchase plan average price per share

$3.88

Percentage of closing price for purchase price of common stock under employee stock purchase plan

85.00%

Issuance of common stock

80,705

Issued warrants to purchase common stock

158,429

Warrant exercise price

5.02

Shares of common stock

340

Issuance of Warrant related to Hercules Note

$1,098

Common_Stock_Summary_of_Stockh

Common Stock - Summary of Stockholders Equity Activity (Detail) (USD $)	1 Months Ended	3 Months Ended		9 Months Ended		87 Months Ended
In Thousands, except Share data, unless otherwise specified	31-May-13	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Schedule Of Stockholders Equity [Line Items]	'	'	'	'	'	'
Beginning Balance, Shares	'	'	'	24,400,754	'	'
Exercise of Common Stock options, Shares	'	'	'	400,157	'	'
Issuance of Common Stock related to the ESPP, Shares	21,505	'	'	'	'	'
Ending Balance, Shares	'	35,255,680	'	35,255,680	'	35,255,680
Beginning Balance, Amount	'	'	'	$22,033	'	'
Exercise of Common Stock options, Amount	'	'	'	680	'	'
Sale of Common Stock under ATM programs, Amount	'	'	'	88,006	'	'
Issuance of Common Stock related to the ESPP, Amount	'	'	'	83	'	'
Stock-based compensation expense, Amount	'	'	'	4,072	'	'
Net loss	'	-7,832	-5,935	-27,360	-18,945	-111,544
Ending Balance, Amount	'	87,514	'	87,514	'	87,514
Common Shares [Member]	'	'	'	'	'	'
Schedule Of Stockholders Equity [Line Items]	'	'	'	'	'	'
Beginning Balance, Shares	'	'	'	24,400,754	'	'
Exercise of Common Stock options, Shares	'	'	'	400,157	'	'
Exercise of Common Stock warrants, Shares	'	'	'	81,045	'	'
Sale of Common Stock under ATM programs, Shares	'	'	'	10,352,219	'	'
Issuance of Common Stock related to the ESPP, Shares	'	'	'	21,505	'	'
Ending Balance, Shares	'	35,255,680	'	35,255,680	'	35,255,680
Beginning Balance, Amount	'	'	'	24	'	'
Exercise of Common Stock options, Amount	'	'	'	1	'	'
Sale of Common Stock under ATM programs, Amount	'	'	'	10	'	'
Ending Balance, Amount	'	35	'	35	'	35
Additional Paid-in Capital [Member]	'	'	'	'	'	'
Schedule Of Stockholders Equity [Line Items]	'	'	'	'	'	'
Beginning Balance, Amount	'	'	'	106,193	'	'
Exercise of Common Stock options, Amount	'	'	'	679	'	'
Sale of Common Stock under ATM programs, Amount	'	'	'	87,996	'	'
Issuance of Common Stock related to the ESPP, Amount	'	'	'	83	'	'
Stock-based compensation expense, Amount	'	'	'	4,072	'	'
Ending Balance, Amount	'	199,023	'	199,023	'	199,023
Deficit Accumulated during Development Stage [Member]	'	'	'	'	'	'
Schedule Of Stockholders Equity [Line Items]	'	'	'	'	'	'
Beginning Balance, Amount	'	'	'	-84,184	'	'
Net loss	'	'	'	-27,360	'	'
Ending Balance, Amount	'	($111,544)	'	($111,544)	'	($111,544)

Common_Stock_Components_of_Sto

Common Stock - Components of Stock-Based Compensation Expense (Detail) (USD $)	9 Months Ended		87 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Total stock-based compensation expense	$4,072	$2,173	$11,584
Employee Awards [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Total stock-based compensation expense	3,174	1,336	6,380
Non-Employee Awards [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Total stock-based compensation expense	758	412	4,171
Non-Employee Warrants [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Total stock-based compensation expense	$140	$425	$1,033

Common_Stock_Summary_of_Stock_

Common Stock - Summary of Stock Option Activity (Detail) (USD $)	9 Months Ended	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2013	Dec. 31, 2012
Summary of stock option activity	'	'
Number of Shares, Beginning of period	2,519,070	'
Number of Shares, Options granted	2,031,590	'
Number of Shares, Options exercised	-400,157	'
Number of Shares, Options cancelled	-20,000	'
Number of Shares, End of period	4,130,503	2,519,070
Number of Shares, Options vested and expected to vest	4,130,503	'
Number of Shares, Options vested and exercisable	1,080,899	'
Weighted Average Exercise Price, Beginning of period	$3.37	'
Weighted Average Exercise Price, Options granted	$6.07	'
Weighted Average Exercise Price, Options exercised	$1.70	'
Weighted Average Exercise Price, Options cancelled	$1.93	'
Weighted Average Exercise Price, End of period	$4.87	$3.37
Weighted Average Exercise Price, Options vested and expected to vest	$4.87	'
Weighted Average Exercise Price, Options vested and exercisable	$3.95	'
Total Weighted Average Intrinsic Value, Beginning of period	$2,860	'
Total Weighted Average Intrinsic Value, End of period	8,830	2,860
Total Weighted Average Intrinsic Value, Options vested and expected to vest	8,830	'
Total Weighted Average Intrinsic Value, Options vested and exercisable	$4,269	'
Weighted Average Remaining Contractual Life	'8 years 7 months 6 days	'8 years 6 months
Weighted Average Remaining Contractual Life, Options vested and expected to vest	'8 years 7 months 6 days	'
Weighted Average Remaining Contractual Life, Options vested and exercisable	'7 years 8 months 12 days	'

Market_Capitalization_Bonuses_1

Market Capitalization Bonuses and Executive Officer Resignations and Agreements - Additional Information (Detail) (USD $)	3 Months Ended			9 Months Ended	3 Months Ended
	Jun. 30, 2013	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013
	Executive Officer Resignations [Member]	Dr. Sandage [Member]	Dr. Glenn Cooper [Member]	Dr. Sandage and Dr. Cooper [Member]	Market Capitalization Bonuses [Member]	Market Capitalization Bonuses [Member]
		Executive Officer Resignations [Member]	Executive Officer Resignations [Member]	Executive Officer Resignations [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]	'	'	'	'	'	'
Market capitalization bonus	'	'	'	'	$312,500	$231,250
Market capitalization	'	'	'	'	250,000,000	125,000,000
Minimum share volume per day	'	'	'	'	100,000	50,000
Trading volume period	'	'	'	'	'30 days	'30 days
Severance costs	445,000	'	'	'	'	'
Severance obligation paid	'	$107,000	$94,900	$446,200	'	'

Lease_Additional_Information_D

Lease - Additional Information (Detail) (New York City Office Lease [Member], USD $)	1 Months Ended
	Apr. 30, 2013
	sqft
New York City Office Lease [Member]	'
Leases [Line Items]	'
Number of year Company entered into lease	'3 years
Office space	1,500
Average annual rent	$122,000
Total rent expense for term	$366,000